Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun-Ichi Imai

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Oncology Reports|June 20, 2018
Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissuesHirosumi Tamura, Arisa Higa, Hirotaka Hoshi, et al.
Biochemical and Biophysical Research Communications|November 18, 2005
CD24 is expressed specifically in the nucleus pulposus of intervertebral discsNobuyuki Fujita, Takeshi Miyamoto, Jun-ichi Imai, et al.
Cancer Research|March 15, 2008
NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cellsNoritaka Yamaguchi, Tetsunari Oyama, Emi Ito, et al.
Anticancer Research|October 28, 2020
A Blood-based Gene-expression Scoring System for Cancer Screening in Patients With Branch-duct Intraductal Papillary Mucinous NeoplasmsRei Suzuki, Hirosumi Tamura, Reiko Honma, et al.
Vaccine|February 7, 2007
Two vaccine toxicity-related genes Agp and Hpx could prove useful for pertussis vaccine safety controlIsao Hamaguchi, Jun-ichi Imai, Haruka Momose, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 15, 2018
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief ReportYuki Owada-Ozaki, Satoshi Muto, Hironori Takagi, et al.
Cancer Immunology, Immunotherapy : CII|December 7, 2019
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancerYuki Ozaki, Satoshi Muto, Hironori Takagi, et al.
FEBS Letters|May 16, 2012
Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogeneMakoto Saito, Yukiko Kato, Emi Ito, et al.
Oncology Letters|February 12, 2021
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burdenSatoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, et al.
Oncology Letters|February 14, 2018
Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptorTakumi Yamaura, Junji Ezaki, Naoyuki Okabe, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Oncology Reports|June 20, 2018
Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissuesHirosumi Tamura, Arisa Higa, Hirotaka Hoshi, et al.
Biochemical and Biophysical Research Communications|November 18, 2005
CD24 is expressed specifically in the nucleus pulposus of intervertebral discsNobuyuki Fujita, Takeshi Miyamoto, Jun-ichi Imai, et al.
Cancer Research|March 15, 2008
NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cellsNoritaka Yamaguchi, Tetsunari Oyama, Emi Ito, et al.
Anticancer Research|October 28, 2020
A Blood-based Gene-expression Scoring System for Cancer Screening in Patients With Branch-duct Intraductal Papillary Mucinous NeoplasmsRei Suzuki, Hirosumi Tamura, Reiko Honma, et al.
Vaccine|February 7, 2007
Two vaccine toxicity-related genes Agp and Hpx could prove useful for pertussis vaccine safety controlIsao Hamaguchi, Jun-ichi Imai, Haruka Momose, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 15, 2018
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief ReportYuki Owada-Ozaki, Satoshi Muto, Hironori Takagi, et al.
Cancer Immunology, Immunotherapy : CII|December 7, 2019
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancerYuki Ozaki, Satoshi Muto, Hironori Takagi, et al.
FEBS Letters|May 16, 2012
Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogeneMakoto Saito, Yukiko Kato, Emi Ito, et al.
Oncology Letters|February 12, 2021
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burdenSatoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, et al.
Oncology Letters|February 14, 2018
Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptorTakumi Yamaura, Junji Ezaki, Naoyuki Okabe, et al.
Pageof 5